Leaflet: information for the user
Olmesartán/Amlodipino/Hidroclorotiazida Krka 20 mg/5 mg/12,5 mg film-coated tablets
Olmesartán/Amlodipino/Hidroclorotiazida Krka 40 mg/5 mg/12,5 mg film-coated tablets
Olmesartán/Amlodipino/Hidroclorotiazida Krka 40 mg/5 mg/25 mg film-coated tablets
Olmesartán/Amlodipino/Hidroclorotiazida Krka 40 mg/10 mg/12,5 mg film-coated tablets
Olmesartán/Amlodipino/Hidroclorotiazida Krka 40 mg/10 mg/25 mg film-coated tablets
olmesartán medoxomilo/amlodipino/hidroclorotiazida
Read this leaflet carefully before you start to take this medicine, because it contains important information for you.
-Keep this leaflet, as you may need to read it again.
-If you have any questions, consult your doctor or pharmacist.
-This medicine has been prescribed for you only, and you must not give it to others even if they have the same symptoms as you, as it may harm them.
-If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. See section 4.
This medicine contains three active substances called olmesartan medoxomilo, amlodipine (as amlodipine besylate) and hydrochlorothiazide. The three substances help control high blood pressure.
The action of these substances contributes to decreasing blood pressure. Olmesartan/hydrochlorothiazide/amlodipine is used to treat high blood pressure:
Do not take Olmesartán/Amlodipino/Hidroclorotiazida Krka if:
Do not take Olmesartán/Amlodipino/Hidroclorotiazida Krka if any of these cases occur.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Olmesartán/Amlodipino/Hidroclorotiazida Krka.
Tell your doctorif you are taking any of the following medications used to treat high blood pressure:
Your doctor may monitor your renal function, blood pressure, and electrolyte levels (e.g., potassium) at regular intervals.
See also the information under the heading “Do not take Olmesartán/Amlodipino/Hidroclorotiazida Krka if:”.
Tell your doctorif you have any of the following health problems:
Contact your doctorif you experience any of the following symptoms:
Like any other medication that lowers blood pressure, excessive lowering of blood pressure in patients with heart or brain circulation problems can cause a heart attack or stroke. Therefore, your doctor will closely monitor your blood pressure.
This medication may cause an increase in lipid and uric acid levels in the blood. Your doctor will likely want to perform blood tests from time to time to monitor these possible changes.
Changes in blood levels of certain chemical substances called electrolytes may occur. Your doctor will likely want to perform blood tests from time to time to monitor this possible change. Some signs of electrolyte changes are: thirst, dry mouth, muscle pain or cramps, tired muscles, low blood pressure (hypotension), feeling weak, slow, tired, drowsy, or restless, nausea, vomiting, decreased need to urinate, rapid heart rate. Tell your doctor if you notice any of these symptoms.
If you are to undergo parathyroid function tests, stop taking this medication before the tests are performed.
It is reported to athletes that this medication contains a component that may result in a positive analytical result for doping control.
Inform your doctor if you are pregnant (or think you may be). Do not recommend the use of this medication at the beginning of pregnancy, and do not take it if you are more than 3 months pregnant, as it may cause serious harm to your baby if taken during this stage (see section “Pregnancy and breastfeeding”).
Children and adolescents (under 18 years)
Olmesartán/Amlodipino/Hidroclorotiazida Krka is not recommended for use in children and adolescents under 18 years.
Other medications and Olmesartán/Amlodipino/Hidroclorotiazida Krka
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any of the following medications:
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any of the following medications for:
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
Taking Olmesartán/Amlodipino/Hidroclorotiazida Krka with food and drinks
Olmesartán/Amlodipino/Hidroclorotiazida Krka can be taken with or without food.
People taking this medication should not consume grapefruit or grapefruit juice. This is because grapefruit and grapefruit juice may cause an increase in the blood levels of the active ingredient amlodipine, which may cause an unpredictable increase in the blood pressure-lowering effect of this medication.
Be careful when drinking alcohol while taking this medication, as some people may feel dizzy, nauseous, or experience headaches. If this happens, do not drink any alcohol.
Older patients
If you are over 65 years old, your doctor will regularly monitor your blood pressure whenever your dose is increased, to ensure that your blood pressure does not drop too low.
Pregnancy and breastfeeding
Pregnancy
Inform your doctor if you are pregnant (or think you may be). Your doctor will advise you to stop taking this medication before becoming pregnant or as soon as you know you are pregnant, and will recommend another medication instead of Olmesartán/Amlodipino/Hidroclorotiazida Krka. Do not recommend the use of this medication during pregnancy, and do not take it if you are more than 3 months pregnant, as it may cause serious harm to your baby if taken during this stage.
If you become pregnant while taking this medication, inform and visit your doctor immediately.
Breastfeeding
Inform your doctor if you are breastfeeding or plan to start breastfeeding. It has been shown that amlodipine and hidroclorotiazida pass into breast milk in small amounts. Do not recommend this medication for mothers who are breastfeeding, and your doctor may choose another treatment if you want to breastfeed.
If you are pregnant, breastfeeding, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Driving and operating machinery
You may feel drowsy, nauseous, or experience headaches while taking this medication for high blood pressure. If this happens, do not drive or operate machinery until the symptoms have disappeared. Consult your doctor.
Olmesartán/Amlodipino/Hidroclorotiazida Krka contains lactose and sodium
This medication contains lactose. If your doctor has told you that you have a certain sugar intolerance, consult with them before taking this medication.
This medication contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially “sodium-free”.
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
If you take more Olmesartán/Amlodipino/Hidroclorotiazida Krka than you should
If you take more tablets than you should, you will probably experience a drop in blood pressure, accompanied by symptoms such as dizziness, and a rapid or slow heart rate.
You may accumulate excess fluid in the lungs (pulmonary edema) causing difficulty breathing that may develop up to 24-48 hours after ingestion.
If you take more tablets than you should or if a child accidentally ingests some tablets, contact your doctor immediately or go to the nearest emergency center and bring with you the packaging of the medication or this leaflet. In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20.
If you forgot to take Olmesartán/Amlodipino/Hidroclorotiazida Krka
If you forgot to take a dose, take the usual dose the next day. Do not take a double dose to compensate for the missed doses.
If you interrupt treatment with Olmesartán/Amlodipino/Hidroclorotiazida Krka
It is essential to continue taking this medication, unless your doctor tells you to stop treatment.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine may cause side effects, although not everyone will experience them. If they occur, they are often mild and do not require interrupting treatment.
The following side effects may be serious, although they affect only a small group of people:
During treatment with Olmesartán/Amlodipino/Hidroclorotiazida, allergic reactions with inflammation of the face, mouth, and/or larynx (vocal cords), along with itching and skin rash may occur.If this happens, stop taking this medicine and consult your doctor immediately..
Olmesartán/Amlodipino/Hidroclorotiazida may cause a pronounced drop in blood pressure in susceptible patients.If this happens, stop taking this medicine, consult your doctor immediately, and remain lying down in a horizontal position.
Unknown frequency: If you experience yellowing of the white of the eyes, dark urine, skin itching, even if you started treatment with Olmesartán/Amlodipino/Hidroclorotiazida some time ago,contact your doctor immediatelywho will evaluate your symptoms and decide how to continue with the treatment for high blood pressure.
This medicine is a combination of three active substances. The following information, first, describes the side effects reported so far with the olmesartán/amlodipino/hidroclorotiazida combination (in addition to those already mentioned) and, second, the known side effects of each of the active substances separately, or when two of the substances are taken together.
To give you an idea of the number of patients who may experience side effects, these have been classified as frequent, infrequent, rare, and very rare.
These are other side effects known so far with olmesartán/amlodipino/hidroclorotiazida:
If these side effects occur, they are often mild andit is not necessary to interrupt treatment.
Frequent
(may affect up to 1 in 10 people)
Upper respiratory tract infection, sore throat, and nose, urinary tract infection, dizziness, headache, perception of heartbeats, low blood pressure, nausea, diarrhea, constipation, cramps, joint swelling, sensation of urgency to urinate, weakness, ankle swelling, fatigue, abnormal laboratory test results.
Infrequent
(may affect up to 1 in 100 people)
Dizziness when getting up, vertigo, rapid heartbeat, sensation of fainting, flushing and sensation of heat in the face, cough, dry mouth, muscle weakness, inability to have or maintain an erection.
These are the side effects known for each of the active substances separately or when two of the substances are taken together:
They may be side effects due to Olmesartán/Amlodipino/Hidroclorotiazida Krka, even if they have not been observed so far with this medicine.
Very frequent
(may affect more than 1 in 10 people)
Edema (fluid retention).
Frequent
(may affect up to 1 in 10 people)
Bronchitis, stomach and intestine infection, vomiting, increased blood sugar, sugar in urine, confusion, drowsiness, visual disturbances (including double vision and blurred vision), nasal secretion or congestion, sore throat, difficulty breathing, cough, abdominal pain, stomach burning, stomach discomfort, flatulence, joint or bone pain, back pain, bone pain, blood in urine, flu-like symptoms, chest pain, pain.
Infrequent
(may affect up to 1 in 100 people)
Reduction in the number of a type of blood cell called platelets, which can cause easy bruising or prolong bleeding time, anaphylactic reactions, abnormal decrease in appetite (anorexia), sleep problems, irritability, mood changes including anxiety, sensation of depression, chills, sleep disorders, alteration of taste, loss of consciousness, decrease in sense of touch, sensation of numbness, worsening of myopia, ringing in the ears (tinnitus), angina (pain or uncomfortable sensation in the chest, known as angina pectoris),irregular heartbeats, rash, hair loss, allergic skin inflammation, skin redness, purple patches or spots on the skin due to small hemorrhages (purpura), skin discoloration, red itchy patches (urticaria), increased sweating, itching, skin rash, skin reactions to light, such as sunburn or skin eruption, muscle pain, urination problems, sensation of needing to urinate at night, breast enlargement in men, decreased libido, swelling of the face, sensation of discomfort, weight gain or loss, fatigue.
Rare
(may affect up to 1 in 1,000 people)
Salivary gland inflammation and pain, decrease in the number of white blood cells in the blood, which could increase the risk of infections, decrease in the number of red blood cells (anemia), bone marrow damage, restlessness, sensation of loss of interest (apathy), seizures (convulsions), yellowish perception of objects when looking at them, dry eyes, blood clots (thrombosis, embolism), fluid accumulation in the lungs, pneumonia, inflammation of small blood vessels and small blood vessels in the skin, pancreatitis, yellowing of the skin and eyes, acute inflammation of the gallbladder, symptoms of lupus erythematosus such as skin rash, joint pain and cold hands and fingers, severe skin reactions including intense skin eruption, urticaria, skin redness, severe itching, blisters, skin peeling, and inflammation, Stevens-Johnson syndrome, toxic epidermal necrolysis, sometimes very severe, movement impairment, acute kidney failure, non-infectious kidney inflammation, kidney function decrease, fever.
Very rare
(may affect up to 1 in 10,000 people)
High muscle tension, numbness of hands or feet, heart attack, stomach inflammation, gum thickening, intestinal obstruction, liver inflammation, acute respiratory distress (signs include severe difficulty breathing, fever, weakness, and confusion).
Unknown frequency
(frequency cannot be estimated from available data)
Decreased vision or eye pain due to high pressure (possible signs of fluid accumulation in the vascular layer of the eye (choroidal hemorrhage) or acute angle-closure glaucoma). Tremors, rigid posture, mask-like face, slow movements, and unsteady gait dragging the feet.
Skin and lip cancer (non-melanoma skin cancer).
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box after CAD. The expiration date is the last day of the month indicated.
This medicationdoes not require special storage conditions.
Medicines should not be thrown down the drains or in the trash. Dispose of the packaging and medicines you no longer need at the SIGRE collection pointof the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. By doing so, you will help protect the environment.
Composition of Olmesartan/Amlodipine/Hydrochlorothiazide Krka
20 mg/5 mg/12,5mg:
Each film-coated tablet contains 20 mg of olmesartan medoxomil, 5 mg of amlodipine (as amlodipine besilate), and 12.5 mg of hydrochlorothiazide.
40 mg/5 mg/12,5mg:
Each film-coated tablet contains 40 mg of olmesartan medoxomil, 5 mg of amlodipine (as amlodipine besilate), and 12.5 mg of hydrochlorothiazide.
40 mg/5 mg/25mg:
Each film-coated tablet contains 40 mg of olmesartan medoxomil, 5 mg of amlodipine (as amlodipine besilate), and 25 mg of hydrochlorothiazide.
40 mg/10 mg/12,5mg:
Each film-coated tablet contains 40 mg of olmesartan medoxomil, 10 mg of amlodipine (as amlodipine besilate), and 12.5 mg of hydrochlorothiazide.
40 mg/10 mg/25mg:
Each film-coated tablet contains 40 mg of olmesartan medoxomil, 10 mg of amlodipine (as amlodipine besilate), and 25 mg of hydrochlorothiazide.
Appearance of the product and contents of the package
20 mg/5 mg/12,5 mg:
The film-coated tablets (tablets) are white or almost white, round, biconvex, with beveled edges.
Dimensions: diameter 8.5 mm ± 0.5 mm.
40 mg/5 mg/12,5 mg:
The film-coated tablets (tablets) are pale yellowish-brown to yellowish-brown, biconvex, capsule-shaped, engraved with the mark “C1” on one face of the tablet.
Dimensions: 15 mm ± 1 mm x 8 mm ± 1 mm.
40 mg/5 mg/25 mg:
The film-coated tablets (tablets) are pale pinkish-orange, biconvex, capsule-shaped, engraved with the mark “C2” on one face of the tablet.
Dimensions: 15 mm ± 1 mm x 8 mm ± 1 mm.
40 mg/10 mg/12,5 mg:
The film-coated tablets (tablets) are pale pink, biconvex, capsule-shaped, engraved with the mark “C3” on one face of the tablet.
Dimensions: 15 mm ± 1 mm x 8 mm ± 1 mm.
40 mg/10 mg/25 mg:
The film-coated tablets (tablets) are pale greyish-violet to greyish-violet, biconvex, capsule-shaped, scored on both faces of the tablet. The tablet can be divided into equal doses.
Dimensions: 15 mm ± 1 mm x 8 mm ± 1 mm.
Olmesartan/Amlodipine/Hydrochlorothiazide Krka is available in packs containing:
Only some package sizes may be marketed.
Marketing authorisation holder
KRKA, d.d., Novo mesto Šmarješka cesta 6, 8501 Novo mesto, Slovenia
Manufacturer responsible
KRKA, d.d., Novo mesto, Smarjeska Cesta 6, 8501 Novo Mesto, Slovenia
TAD Pharma GmbH, Heinz-Lohmann-Strasse 5, Groden Cuxhaven 27472, Germany
For further information about this medicinal product, please contact the local representative of the marketing authorisation holder:
KRKA Farmacéutica, S.L., Calle de Anabel Segura 10, 28108 Alcobendas, Madrid, Spain
This medicinal product is authorised in the member states of the European Economic Area with the following names:
Member state | Medicinal product name |
Danish | Olmesartan/Amlodipin/ Hydrochlorthiazid Krka |
Dutch | Olmesartan/Amlodipine/HCTZ Krka 20 mg/5 mg/12,5 mg filmomhulde tabletten Olmesartan/Amlodipine/HCTZ Krka 40 mg/5 mg/12,5 mg filmomhulde tabletten Olmesartan/Amlodipine/HCTZ Krka 40 mg/5 mg/25 mg filmomhulde tabletten Olmesartan/Amlodipine/HCTZ Krka 40 mg/10 mg/12,5 mg filmomhulde tabletten Olmesartan/Amlodipine/HCTZ Krka 40 mg/10 mg/25 mg filmomhulde tabletten |
German | OlmeAmlo HCT 20 mg/5 mg/12,5 mg Filmtabletten OlmeAmlo HCT 40 mg/5 mg/12,5 mg Filmtabletten OlmeAmlo HCT 40 mg/5 mg/25 mg Filmtabletten OlmeAmlo HCT 40 mg/10 mg/12,5 mg Filmtabletten OlmeAmlo HCT 40 mg/10 mg/25 mg Filmtabletten |
Estonian | Olsitri |
Greek | Pollaplo HCT 20 mg/5 mg/12,5 mg επικαλυμμ?να με λεπτ? υμ?νιο δισκ?α Pollaplo HCT 40 mg/5 mg/12,5 mg επικαλυμμ?να με λεπτ? υμ?νιο δισκ?α Pollaplo HCT 40 mg/5 mg/25 mg επικαλυμμ?να με λεπτ? υμ?νιο δισκ?α Pollaplo HCT 40 mg/10 mg/12,5 mg επικαλυμμ?να με λεπτ? υμ?νιο δισκ?α Pollaplo HCT 40 mg/10 mg/25 mg επικαλυμμ?να με λεπτ? υμ?νιο δισκ?α |
Spanish | Olmesartán/Amlodipino/Hidroclorotiazida Krka 20 mg/5 mg/12,5 mg comprimidos recubiertos con película EFG Olmesartán/Amlodipino/Hidroclorotiazida Krka 40 mg/5 mg/12,5 mg comprimidos recubiertos con película EFG Olmesartán/Amlodipino/Hidroclorotiazida Krka 40 mg/5 mg/25 mg comprimidos recubiertos con película EFG Olmesartán/Amlodipino/Hidroclorotiazida Krka 40 mg/10 mg/12,5 mg comprimidos recubiertos con película EFG Olmesartán/Amlodipino/Hidroclorotiazida Krka 40 mg/10 mg/25 mg comprimidos recubiertos con película EFG |
Irish | Olmesartan Medoxomil/Amlodipine/ Hydrochlorothiazide Krka 20 mg/5 mg/12.5 mg film-coated tablets Olmesartan Medoxomil/Amlodipine/ Hydrochlorothiazide Krka 40 mg/5 mg/12.5 mg film-coated tablets Olmesartan Medoxomil/Amlodipine/ Hydrochlorothiazide Krka 40 mg/5 mg/25 mg film-coated tablets Olmesartan Medoxomil/Amlodipine/ Hydrochlorothiazide Krka 40 mg/10 mg/12.5 mg film-coated tablets Olmesartan Medoxomil/Amlodipine/ Hydrochlorothiazide Krka 40 mg/10 mg/25 mg film-coated tablets |
Lithuanian | Olsitri 20 mg/5 mg/12,5 mg plevele dengtos tabletes Olsitri 40 mg/5 mg/12,5 mg plevele dengtos tabletes Olsitri 40 mg/5 mg/25 mg plevele dengtos tabletes Olsitri 40 mg/10 mg/12,5 mg plevele dengtos tabletes Olsitri 40 mg/10 mg/25 mg plevele dengtos tabletes |
Latvian | Olsitri 20 mg/5 mg/12,5 mg apvalkotas tabletes Olsitri 40 mg/5 mg/12,5 mg apvalkotas tabletes Olsitri 40 mg/5 mg/25 mg apvalkotas tabletes Olsitri 40 mg/10 mg/12,5 mg apvalkotas tabletes Olsitri 40 mg/10 mg/25 mg apvalkotas tabletes |
Portuguese | Amlodipina + Olmesartan medoxomilo + Hidroclorotiazida Krka |
Romanian | Olsitri 20 mg/5 mg/12,5 mg comprimate filmate Olsitri 40 mg/5 mg/12,5 mg comprimate filmate Olsitri 40 mg/5 mg/25 mg comprimate filmate Olsitri 40 mg/10 mg/12,5 mg comprimate filmate Olsitri 40 mg/10 mg/25 mg comprimate filmate |
Slovenian | Olsitri 20 mg/5 mg/12,5 mg filmsko obložene tablete Olsitri 40 mg/5 mg/12,5 mg filmsko obložene tablete Olsitri 40 mg/5 mg/25 mg filmsko obložene tablete Olsitri 40 mg/10 mg/12,5 mg filmsko obložene tablete Olsitri 40 mg/10 mg/25 mg filmsko obložene tablete |
Last review date of this leaflet:November 2022
For detailed information about this medicinal product, please visit the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://aemps.gob.es/
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.